tbuckley/cabot-search huggingface dataset:
Low hepatitis B virus–specific T‐cell response in males correlates with high regulatory T‐cell numbers in murine models
Authors: Anna D. Kosinska, Leila Pishraft‐Sabet, Weimin Wu, Zhong Fang, Marzena Lenart, Jieliang Chen, Kirsten K. Dietze, Cong Wang, Thekla Kemper, Yong Lin, Shiou‐Hwei Yeh, Jia Liu, Ulf Dittmer, Zhenghong Yuan, Michael Roggendorf, Mengji Lu
Journal: Hepatology (2017)

Hepatitis B virus (HBV) infection shows significant gender‐related differences in pathogenesis, disease progression, and development of hepatocellular carcinoma. The gender‐associated differences in HBV replication and viral protein levels may be associated with distinct HBV‐specific immune responses in the host. In the present study, we examined the impact of gender on HBV‐specific immune responses in two different mouse models representing transient and persistent hepadnaviral infection; hydrodynamic injection with the HBV genome mimicked acute HBV infection, whereas the efficacy of therapeutic vaccination was studied in the woodchuck hepatitis virus transgenic mouse model. Consistent with previous reports, significantly higher HBV DNA and protein levels were detected in male compared to female mice. Although hydrodynamic injection with the HBV genome resulted in similar numbers of intrahepatic HBV‐specific cluster of differentiation 8–positive (CD8 + ) T cells, their functionality was significantly reduced in males and correlated with higher numbers of intrahepatic regulatory T cells (Tregs). Similar effects were observed in woodchuck hepatitis virus transgenic mice immunized with a DNA prime‐recombinant adenovirus boost vaccination protocol. Male mice showed functionally suppressed woodchuck hepatitis virus–specific CD8 + T‐cell responses in the liver and significantly higher numbers of intrahepatic Tregs compared to females. Blockade of Treg responses in male mice led to augmented effector functions of specific CD8 + T cells and subsequently improved virus control in both models of transient and persistent hepadnaviral infection. Conclusion : The functionality of virus‐specific CD8 + T cells in male mice was suppressed by intrahepatic Tregs and inversely correlated with levels of hepadnaviral DNA and viral protein; the induction of intrahepatic Tregs by viral replication and/or protein levels may explain the gender‐related differences in the outcomes of HBV infection and limit the success of immunotherapeutic strategies in male patients. (H epatology 2017;66:69–83).
THE ASSOCIATION BETWEEN ECHOCARDIOGRAPHIC LABORATORY ACCREDITATION AND THE QUALITY OF IMAGING AND REPORTING
Authors: Jeremy Thaden, Michael Tsang, Chadi Ayoub, Ratnasari Padang, Vuyisile Nkomo, Stephen Tucker, Cynthia Cassidy, Merri Bremer, Garvan Kane, Patricia Pellikka
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF FINAL MINIMAL STENT AREA BY IVUS ON 3-YEAR OUTCOME AFTER PCI OF LEFT MAIN CORONARY ARTERY DISEASE: THE EXCEL TRIAL
Authors: Akiko Maehara, Gary Mintz, Patrick Serruys, A. Kappetein, David Kandzari, Erick Schampaert, Ad Van Boven, Ferenc Horkay, Imre Ungi, Samer Mansour, Adrian Banning, David Taggart, Manel Sabaté, Anthony Gershlick, Andrzej Bochenek, Jose Pomar, Nicholas Lembo, Nicolas Noiseux, John Puskas, W. Morris Brown, Roxana Mehran, Ori Ben-Yehuda, Charles Simonton, Joseph Sabik, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen.
Authors: Joanna Schaenman, Marcy L. Vana, Chanu Rhee, Jonathan Wong, Shelly Navato, Laura J. Johnston, Ruby M. Wong, Dora Y. Ho, Janice (Wes) Brown
Journal: Blood (2008)
Is tumor necrosis necessary to achieve a response in refractory tumors treated with intralesionally photoactivated talaporfin sodium (IPTS)?
Authors: J. P. Smith
Journal: Journal of Clinical Oncology (2004)

8238 Background: Response to IPTS therapy, an investigational method proposed for treating refractory, bulky tumors, may differ from the typical necrosis pattern seen with radio-frequency ablation. To determine whether tumor necrosis is required to achieve a response to IPTS therapy, I performed the following analysis of the CT imaging findings from a Phase I safety study of IPTS. Methods: 21 patients with refractory, bulky tumors of varying histologic types were treated with IPTS by means of a light-emitting diode (LED) array placed percutaneously using CT guidance. The treatment zone was limited to a region within the tumor border. Contrast-enhanced CT studies were acquired on days 0, 7, 14, and 42. 19 of the 21 patients (90%) enrolled completed the study. Each tumor was assessed serially by measuring its longest dimension and by noting the extent of tumor necrosis as compared with the baseline measurement. Assessments were performed jointly by the principal investigator (PI) and a radiologist at each study site and separately, by a blinded, independent radiologist. Results: CT revealed that by day 42, 12 of the 19 (63%) evaluable tumors showed decreased tissue attenuation in the treatment zone consistent with tumor necrosis. Tumor responses, as assessed by two blinded radiologists included 6 Partial Responses (PR), 10 Stable Disease (SD), and 2 Disease Progression (PD), yielding an overall response rate of 33%. Tumor responses as assessed by site radiologists included 1 Complete Response (CR), 8 PRs, 8 SDs, and 1 PD, yielding an overall response rate of 50%. Conclusions: IPTS therapy of bulky, refractory tumors yielded overall response rates of 33% (blinded independent radiologists) and 50% (site radiologists). The CT findings included size reduction with necrosis in the treatment zone in 7/19 (37%), size reduction without necrosis in 5/19 (26%), necrosis without size reduction in 5/19 (26%), size increase without necrosis in 1/19 (5%), and no apparent change in 1/19 (5%). The majority of lesions treated with IPTS showed a reduction in size without necrosis. Necrosis as shown by CT is not necessary for a treatment response. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration . Light Sciences, Inc. Light Sciences
Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers.
Authors: Patrick Lawson Stevens, Daniel John Lenihan, Bonnie Ky, Carla L. Warneke, Marcy M Johnson, Vandana Gupta Abramson, Ingrid A. Mayer, Paul T. Adams, Mark G. Campbell, Puneet S. Cheema, Dennis Frederic Moore, Chilakamarri Yeshwant, Joseph R. Carver, Michael Fisch
Journal: Journal of Clinical Oncology (2014)

9644 Background: Anthracyclines (ANTH) are widely used as cancer therapies but carry a significant risk of heart failure (HF) and left ventricular dysfunction (LVD). Improved cardiovascular (CV) risk stratification is necessary to decrease the growing incidence of CV and oncologic morbidity during ANTH chemotherapy. The overall objective of this study was to define the utility of cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI) in the identification of subsequent ANTH cardiotoxicity. Methods: The PREDICT study was a multicenter, prospective cohort of 586 patients initiating ANTH chemotherapy. Patients underwent serial biomarker evaluation at baseline, before each chemotherapy cycle, and at 6 and 12 months. Echocardiography was performed at baseline, 6 months, and 12 months, or for suspected CV events. CV events were defined as symptomatic HF, asymptomatic LVD, acute coronary syndrome, symptomatic arrhythmia, or cardiac death. Results: At baseline, the median BNP was 17pg/ml (range 0.5-188pg/ml) and 95% of participants had a TnI <0.05ng/ml. At baseline or during chemotherapy or follow-up, 17% had a BNP >100pg/ml and 41% had a TnI>0.05ng/ml. Overall, 63 patients (11%) suffered a CV event. In univariate analysis, a baseline BNP >100 pg/ml was associated with cardiotoxicity (OR 3.6, 95% CI 1.4-9.0, p=0.007) as was an elevated BNP >100 pg/ml at any time during or after therapy (OR 3.2, 95% CI 1.8-5.6, p<0.0001). Elevations in TnI at baseline or during therapy or follow-up were not associated with cardiotoxicity (p=0.52; 0.98, respectively). BNP demonstrated a high specificity and negative predictive value (Table), whereas TnI had less discriminative ability. Conclusions: Elevations in BNP were significantly associated with cardiotoxicity in patients undergoing ANTH chemotherapy and appeared superior to TnI. Cardiac biomarker assessment in addition to other clinical factors may assist in the identification of ANTH cardiotoxicity. Clinical trial information: NCT01311843.Diagnostic performance of BNP and TnI in predicting cardiac events. Marker Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) BNP > 100 pg/ml 35 (23, 48) 85 (81, 88) 22 (14, 31) 92 (89, 94) TnI > 0.05 ng/ml 41 (29, 54) 59 (54, 63) 11 (7, 15) 89 (85, 92)
CORONARY ARTERY DISEASE LEARNING AND ALGORITHM DEVELOPMENT STUDY: EARLY ANALYSIS OF EJECTION FRACTION EVALUATION
Authors: Robi Goswami, Thomas Stuckey, Frederick Meine, Narendra Singh, Jeremiah Depta, Sunny Gupta, Shyam Ramchandani, R. Susan Crawford, Tim Burton, William E. Sanders
Journal: Journal of the American College of Cardiology (2017)
USE OF MODERN SCORES TO EVALUATE INDIVIDUAL RISK/BENEFIT OF PROLONGED DUAL ANTIPLATELET THERAPY MAY MODIFY DUAL ANTI-PLATELET THERAPY DURATION IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS
Authors: Cecile Caze, Gregoire Range, Theodora Bejan-Angoulvant, Denis Angoulvant
Journal: Journal of the American College of Cardiology (2017)
Neoplastic disease in fertile age: Psychological support during the course of the mother-child experience
Authors: R. Biamonte, A. Piattello, S. Pignata, B. Costantini, G. Conte, D. Barberio, S. Palazzo, F. De Falco, G. Scambia
Journal: Journal of Clinical Oncology (2004)

8235 Background: Because of the progressive rise in the mean age of the first delivery and the progressive lowering in the age of onset of tumors, the continuous increas in the number of patients with children in infancy or adolescence is clear. Methods: In the months of July-August 2002,the research Institute ISI Research, carried out an analysis of the needs of women with oncological pathology by filling out a form given to 80 Oncologists and 20 Haematologists. 1186 Italian oncological patients were assessed (917 women affected by solid tumours and 269 by haematological neoplasia) as a representative sample of the different national geographic areas. Because of the progressive rise in the mean age of the first delivery and the progressive lowering in the age of onset of tumours, the continuous increase in the number of patients with children in infancy or adolescence is clear. Results: 69.5% of the women interviewed are of fertile age including 95.2% with children and 37.1% of them referring to notable problems in the management of the situation during the course of oncological treatment. Conclusions: The realization of the project “Neoplastic pathology in fertile age: psychological support during the course of the mother-child experience” provides for: 1)the involvement of a series of Italian Oncological Centres in which suitable living environments will be set up suitable to the needs of mother-children and woman-family and to the entertainment of the children during the course of oncological treatment; 2)specialized work carried out, after an initial assessment of the overall needs both of the mother and of the child, using a methodology set up by a group of expert Psychoncologists. Individual and group actions are provided for patients: psychological support, relaxation techniques, psycho-educational provision, psycho-emotional support. Actions by means of “baby-observation” techniques and other assessment methodologies of the emotional state of the child are provided for the children. The results achieved should constitute the basis of the guidelines. No significant financial relationships to disclose.
INCREASED TUMOR NECROSIS FACTOR-A LEVELS IN PATIENTS WITH CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICES MEDIATE VASCULAR INSTABILITY AND ARE ASSOCIATED WITH HIGHER NON-SURGICAL BLEEDING
Authors: Corey Tabit, Mitchell Coplan, Phetcharat Chen, Valluvan Jeevanandam, Nir Uriel, James Liao
Journal: Journal of the American College of Cardiology (2017)
EMPLOYING THE MULTIDISCIPLINARY HEART TEAM APPROACH FOR COMPLEX CORONARY ARTERY DISEASE: A SINGLE CENTER EXPERIENCE
Authors: Michael Young, Elizabeth Laikhter, Kevin Sinclair, Mary Cadigan, Eugene Pomerantsev, Michael Fifer, Thoralf Sundt, Robert Yeh, Farouc Jaffer
Journal: Journal of the American College of Cardiology (2017)
Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases
Authors: A. C. Yopp, J. Shia, P. J. Allen, R. P. DeMatteo, W. R. Jarnagin, Y. Fong, L. Blumgart, M. I. D'Angelica
Journal: Journal of Clinical Oncology (2009)

11081 Background: Expression of the chemokine receptors CXCR4 and CCR7 has been associated with metastases and poor prognosis in primary tumors but their relevance in colorectal liver metastases (CLM) is unclear. This study examines the relationship between tumor chemokine receptor expression, pattern of recurrence and outcome after resection of hepatic metastases.Methods: Eighty patients with metastases from colon or rectal primary tumors who underwent a R 0 partial hepatectomy from February 2002 to April 2004 were studied prospectively. Immunohistochemical staining was performed on the formalin-fixed, paraffin-embedded tissues of hepatic metastases using antibodies specific for CXCR4, CXCL12 and CCR7. The correlation between the CXCR4, CXCL12 and CCR7 expression and clinicopathological factors was evaluated.Results: Median follow-up was 42.9 months. Positive expression of CXCR4, CXCL12 and CCR7 was seen in 49 (61%), 23 (29%) and 48 (60%) of tumor specimens, respectively. Clinical risk score greater than 2 and high CXCR4 expression were associated with a shorter disease-specific survival (DSS) and a reduced recurrence-free survival (RFS) following partial hepatectomy for CLM (p&lt;0.05) by multivariate analysis. CCR7 and CXCL12 expression, hepatic artery infusion pump chemotherapy, systemic chemotherapy and site of primary disease did not influence DSS or RFS. Fifty-three (68%) of the patients recurred; 11 with liver only recurrences, 25 with lung only recurrences and 18 with multiple sites of recurrences. High expression of CXCR4 is associated with widespread multiple sites of recurrence ( Table ).Conclusions: CXCR4 expression in colorectal hepatic metastases adds prognostic information with regards to DSS, RFS and patterns of recurrence and may play role in clinical decision making regarding chemotherapy and surgical interventions. CXCR4 expression may also provide additional prognostic information beyond the already validated clinical risk score. [Table: see text] No significant financial relationships to disclose.
IS IT SAFE TO USE HIGH-SENSITIVITY CARDIAC TROPONIN T TO RULE OUT MYOCARDIAL INFARCTION AT PRESENTATION?
Authors: Dennis Sandeman, Anoop Shah, Lorraine Dinnel, Jack Andrews, Bappa Roy, Philip Wenham, Ken Campbell, Mary Jarvie, Atul Anand, Robert Cargill, Mark Francis, Andrew Chapman, Nicholas Mills
Journal: Journal of the American College of Cardiology (2017)
UNLOADING THE LEFT VENTRICLE: A CASE OF MECHANICAL CIRCULATORY SUPPORT IN ACUTE AORTIC INSUFFICIENCY
Authors: Shashank Jain, Menhel Kinno, Shervin Golbari, Eric Somberg, Ellie Elmann, Eugene Bunnell, Samantha Brenner, Kumar Satya
Journal: Journal of the American College of Cardiology (2017)
INITIAL USE OF THE EVOLUT PRO SELF-EXPANDING TRANSCATHETER AORTIC VALVE
Authors: John Kiene Forrest, Abeel Mangi, Jeffrey Popma, Kamal Khabbaz, Michael Reardon, Neal Kleiman, Steven Yakubov, Daniel Watson, Susheel Kodali, Isaac George, Peter Tadros, George Zorn, John Brown, Robert Kipperman, Cezar Staniloae, Mathew Williams
Journal: Journal of the American College of Cardiology (2017)
Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring
Authors: Stephanie Dubruille, Cindy Kenis, Yves Libert, Michel Delforge, Catherine Choffray, Myriam Roos, Aurélie Collard, Nathalie Meuleman, Marie Maerevoet, Darius Razavi, Hans Wildiers, Dominique Bron
Journal: Blood (2016)
IMPACT OF CARDIAC TROPONIN I ON THE PRESENCE OF THE CORONARY ARTERY PLAQUE IN RHEUMATOID ARTHRITIS PATIENTS
Authors: Negin Nezarat, Dong Li, Matthew Budoff, Rine Nakanishi, Nasim Sheidaii, Sina Rahmani, Kazuhiro Osawa, Hong Qi, Michael Kim, Eranthi Jayawardena, Nicolai Hathiramani, Ferdinand Flores, George Karpouzas
Journal: Journal of the American College of Cardiology (2017)
Poster Session 3: Hepatitis B: Epidemiology and Natural History History
Journal: Hepatology (2015)

Purpose Hepatitis B virus is one of the main risk factors for hepatocellular carcinoma (HCC).The antivirals entecavir and tenofovir achieve viral suppression in most chronic hepatitis B (CHB) patients, however their effect in HCC remains unclear.Our aim was to assess HCC incidence and risk factors for HCC in CHB.Methods Retrospective study of a cohort of CHB patients treated with ETV or TDF at a single center, between 2008 and 2015.The patients performed regular HCC screening with ultrasound and HCC diagnosis was established according to international guidelines.Statistical analysis with SPSS; A=0.05 Results Cohort of 143 CHB patients, 68% male, with mean age 51±14 years, 27% with cirrhosis and 17% HBeAg positive.There was a baseline diagnosis of HCC at the time of antiviral therapy start in 7 (5%) patients.During a median follow-up of 57 months 92% of patients achieved viral suppression with a median time of 7 months of treatment.The global HCC incidence was 4.4% (6/136) and the annual incidence was 0.8%.The median time for HCC development (Figure ) was 31 months (IQR 22-49 months) and in 5 patients HCC occurred after a median time of 33 months (IQR 24-52 months) with negative HBV-DNA.HCC incidence was higher in cirrhotic patients (global -15.6%; 3.8% per year) than in patients without cirrhosis (global 1%; 0.2% per year), p<0.001,OR=19.1.The risk was also associated with age as HCC patients were older (mean age 67 vs 49 years, p=0.002).Conclusions Although antiviral therapy was highly effective, there was an increased HCC incidence, even after several years of viral suppression.This risk was higher in older patients and in patients with cirrhosis.Our study highlights the importance of regular HCC screening, even with maintained HBV-DNA suppression.
THIRTY-DAY READMISSIONS FOLLOWING ENDOVASCULAR OR SURGICAL TREATMENT FOR CRITICAL LIMB ISCHEMIA: ANALYSIS OF THE NATIONWIDE READMISSIONS DATABASE
Authors: Dhaval Kolte, Mehdi Shishehbor, Kevin Kennedy, Peter Soukas, J. Abbott, Douglas Drachman, Shafiq Mamdani, Sahil Khera, Omar Hyder, Herbert Aronow
Journal: Journal of the American College of Cardiology (2017)
ECHOCARDIOGRAPHIC EVIDENCE FOR LEFT VENTRICULAR RECOVERY AFTER REFRACTORY VENTRICULAR FIBRILLATION CARDIAC ARREST TREATED WITH PRIMARY ANGIOPLASTY AND EXTRACORPOREAL MEMBRANE OXYGENATION
Authors: Kathleen Carlson, Luis Felipe N. Kazmirczak, Jason Bartos, Cindy Martin, Ganesh Raveendran, K. Madhu, John Ranjit, Emil Missov, Demetris Yannopoulos
Journal: Journal of the American College of Cardiology (2017)
PULSE PRESSURE AS A PREDICTOR OF RENAL FUNCTION PROGRESSION OVER 3-YEAR FOLLOW-UP IN AFRICAN AMERICAN POPULATION
Authors: Wasawat Vutthikraivit, Pattara Rattanawong, Possawat Vutthikraivit, Prabhakorn Kitbhoka, Nattachai Suwachittanont, Tepsiri Chongkrairatanakul
Journal: Journal of the American College of Cardiology (2017)
SELF-REPORTED MORISKY EIGHT ITEM MEDICATION ADHERENCE SCALE FOR STATINS CONCORDS WITH PILL COUNT METHOD AND CORRELATES WITH SERUM LIPID PROFILE PARAMETERS AND SERUM HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE LEVELS
Authors: Abhinav Grover, Harmeet Rehan, Madhur Yadav, Lalit Gupta
Journal: Journal of the American College of Cardiology (2017)
Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer
Authors: B. Burtness, R. Sipples, G. Mirto, L. Thomas, Z. Rahman, R. A. Kloss, J. Murren, J. Lacy
Journal: Journal of Clinical Oncology (2004)

4116 Background: Docetaxel (D) and irinotecan (I) are among novel agents with activity in pancreatic cancer. Combination D/I is attractive because of preclinical evidence of synergy and because of non-overlapping toxicities. We have previously demonstrated safety and tolerability of D 35 mg/m2 and I 50 mg/m2 given on days (d) 1, 8, 15, and 21 of a 35 d schedule. We have enrolled 37 patients (pts) on a phase II study of this regimen for pts with advanced pancreatic cancer. Methods: Pts were eligible who had unresectable or metastatic adenocarcinoma of the pancreas, bidimensionally measurable disease, ECOG performance status 0–2, ANC > 1500/microl, AST < 5 x upper limit of normal (ULN), alkaline phosphatase < 2.5 x ULN, and normal bilirubin. Tumor assessment was performed with CT, CT angiography or MR every 2 cycles. Response was graded according to WHO criteria. Results: We enrolled 37 pts. 1 was ineligible on pathology review. Principle toxicities were diarrhea, neutropenia, and hyperglycemia. There were no toxic deaths. There were 4 early deaths: 2 pulmonary emboli, 1 sudden death and 1 cerebrovascular accident. These pts are included in response analysis. 2 pts who are too early and 1 who withdrew are not. Among 33 evaluable pts, there were 7 (21.2%) who attained partial response and 1 (3.0%) who attained a complete response for an objective response rate of 24.2%. 13 (39.4%) had stable disease at 12 weeks and 7 (21.2%) had progressive disease at first reevaluation. Median survival is 8.7 months (m) (range 0–34+ m). 12 pts remain alive at 0–34 months. The pt who attained CR is alive at 34 m and has been off chemotherapy for 11.5 months without evidence of recurrence on MR or PET. Conclusions: D/I combination given on a weekly schedule is a promising treatment for advanced pancreatic cancer. E8200 is a randomized phase II cooperative group trial, currently accruing, which explores this regimen with or without the addition of cetuximab. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Pharmaceuticals Aventis Pharmaceuticals Aventis; Pfizer
Phase II Study of Epigenetic Therapy with Hydralazine and Valproate in Cutaneous T-Cell Lymphoma
Authors: Ramiro Espinoza, Manuel Aguilar Rodríguez, Nidia P. Zapata, Jorge Carlos Torres, Diana Berenice Nolasco, Silvia Eugenia Alarcon Barrios, Eduardo Cervera, Myrna Candelaria, Valentin Lozano, Alejandro Sosa, Javier Espinoza, Magnolia Vieyra, Jorge Gutierrez, Luis Mario Sosa, Reynaldo González, Luis Oñate, Juan Labardini
Journal: Blood (2016)
TAVR USING TRANSCAROTID VASCULAR ACCESS: IN-HOSPITAL AND INTERMEDIATE TERM OUTCOMES
Authors: Keith B. Allen, Adnan Chhatriwalla, David Cohen, Zuhair Hawa, Sanjeev Aggarwal, Suzanne Baron, Anthony Hart, James Mitchell, Zafir Hawa, John Davis, A. Michael Borkon
Journal: Journal of the American College of Cardiology (2017)